994 related articles for article (PubMed ID: 1415443)
1. The metabolic impact of oral contraceptives.
Krauss RM; Burkman RT
Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1177-84. PubMed ID: 1415443
[TBL] [Abstract][Full Text] [Related]
2. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
Crook D; Godsland IF; Wynn V
Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
[TBL] [Abstract][Full Text] [Related]
3. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
[TBL] [Abstract][Full Text] [Related]
4. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L
Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417
[TBL] [Abstract][Full Text] [Related]
5. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
[TBL] [Abstract][Full Text] [Related]
6. A norgestimate-containing oral contraceptive: review of clinical studies.
Kafrissen ME
Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
[TBL] [Abstract][Full Text] [Related]
7. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
[TBL] [Abstract][Full Text] [Related]
8. The role of triphasic levonorgestrel in oral contraception: a review of metabolic and hemostatic effects.
Lachnit-Fixson U
Gynecol Endocrinol; 1996 Jun; 10(3):207-18. PubMed ID: 8862497
[TBL] [Abstract][Full Text] [Related]
9. Lipids, cardiovascular disease, and oral contraceptives: a practical perspective.
Upton GV
Fertil Steril; 1990 Jan; 53(1):1-12. PubMed ID: 2403935
[TBL] [Abstract][Full Text] [Related]
10. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
[TBL] [Abstract][Full Text] [Related]
11. Lipids and cardiovascular disease: do the findings and therapy apply equally to men and women?
LaRosa JC
Womens Health Issues; 1992; 2(2):102-11; discussion 111-3. PubMed ID: 1617306
[TBL] [Abstract][Full Text] [Related]
12. [Lipids, lipoproteins, arterial accidents and oral contraceptives].
Bakir R; Hilliquin P
Contracept Fertil Sex (Paris); 1986 Jan; 14(1):81-7. PubMed ID: 12341243
[TBL] [Abstract][Full Text] [Related]
13. Effects of estrogens and progestogens on lipid metabolism.
Oster P; Arab L; Kohlmeier M; Mordasini R; Schellenberg B; Schlierf G
Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):773-5. PubMed ID: 7065057
[TBL] [Abstract][Full Text] [Related]
14. [Influence of progestins on adverse effects of oral contraceptives].
Wynn V
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
[TBL] [Abstract][Full Text] [Related]
15. [Metabolic risks of oral contraception].
Monier L
Rev Int Pediatr; 1988 Feb; (178):64-5. PubMed ID: 12282576
[TBL] [Abstract][Full Text] [Related]
16. Contraception for women with diabetes: an update.
Skouby SO; Mølsted-Pedersen L; Petersen KR
Baillieres Clin Obstet Gynaecol; 1991 Jun; 5(2):493-503. PubMed ID: 1954724
[TBL] [Abstract][Full Text] [Related]
17. The effect of progestins in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins.
Wynn V; Niththyananthan R
Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):766-71. PubMed ID: 6801982
[TBL] [Abstract][Full Text] [Related]
18. Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives.
Spellacy WN
Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):732-4. PubMed ID: 7039318
[TBL] [Abstract][Full Text] [Related]
19. Fasting plasma lipids, lipoproteins and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives.
Oyelola OO
Contraception; 1993 May; 47(5):445-54. PubMed ID: 8513671
[TBL] [Abstract][Full Text] [Related]
20. Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease.
Gaspard UJ; Lefebvre PJ
Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):334-43. PubMed ID: 2196805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
